The GT brand, founded in 2013 (United States), from 2 sister brands and 2214 competing brands. GT is owned by Galectin Therapeutics, listed on the stock exchange of New York GT is part of the Biotechnology activity sector.
Investment simulator :
Portfolio valuation
Galectin Therapeutics
(GT)
over 5 years*
USD 2.63